MétaCan
Menu
Back to cohort

Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim

2024· article· en· W4396515165 on OpenAlexfundno aff
Heather E. Stefanski, Michelle Kuxhausen, Stephanie Bo‐Subait, Hati Kobusingye, Deborah Mattila, Jennifer Schenfeld, Darcie Sandschafer, Linda J. Burns, Bronwen E. Shaw, Michael A. Pulsipher, J. Philip Miller, Steven M. Devine

Bibliographic record

VenueBlood Advances · 2024
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsnot available
FundersNational Institute of Environmental Health SciencesNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchLegend BiotechPharmacyclicsTakeda OncologyHealth Resources and Services AdministrationMorphoSysSwedish Orphan BiovitrumVertex PharmaceuticalsOmeros CorporationAstellas PharmaAdaptive BiotechnologiesPfizerIncyteKiadis Pharmabluebird bioJazz PharmaceuticalsStemCyteActinium PharmaceuticalsCareDxNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationBristol-Myers SquibbCSL BehringBeiGeneHistoGeneticsAtara BiotherapeuticsNational Cancer InstituteGilead SciencesSanofiGlaxoSmithKlineGateway for Cancer ResearchMallinckrodt PharmaceuticalsAstellas Pharma USAmgen
KeywordsFilgrastimTerm (time)Peripheral bloodStem cellPeripheral Blood Stem CellsMedicineImmunologyInternal medicineGranulocyte colony-stimulating factorHematopoietic stem cell transplantationBiologyTransplantationGenetics

Abstract

fetched live from OpenAlex

ABSTRACT: Allogeneic hematopoietic cell transplantation is a life-saving procedure used to treat a variety of devastating diseases. It requires hematopoietic stem cells collected via filgrastim-mobilized peripheral blood stem cells (PBSCs) or bone marrow (BM) harvest from volunteer unrelated donors (URDs). There is a paucity of safety data regarding donors' long-term adverse events. This prospective, observational study combined PBSC donors enrolled in the NMDP Investigational New Drug trial and BM donors between 1 July 1999 and 30 September 2015. The primary objective was to describe the long-term incidence of myeloid malignancies. The secondary objectives included describing the long-term incidence of lymphoid malignancies, nonhematologic malignancies, autoimmune disorders, and thrombotic events. A total of 21 643 donors (14 530 PBSCs and 7123 BM) were included. The incidence rate of myeloid disorders per 100 000 person-years in donors of PBSCs was 2.53 (95% confidence interval [CI], 0.82-7.84) and in donors of BM, it was 4.13 (95% CI, 1.33-12.8). The incidence rate ratio of PBSCs/BM donors was 0.61 (95% CI, 0.12-3.03; P = .55). The incidence of other malignancies, autoimmunity, and thrombosis did not differ between the donor types. This comprehensive study of the long-term effects of filgrastim in URDs of PBSCs provides strong evidence that donors who receive filgrastim are not at an increased risk of these events compared with BM donors. It also provides reassurance to current donors undergoing stem cell mobilization as well as individuals considering joining stem cell registries, such as NMDP.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.631
Threshold uncertainty score0.706

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.270
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207